Lung cancer is one of the most common malignancies in men and women and a cause for global mortality with approximately over 200,000 new cases diagnosed in 2020. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer responsible for over 80% of cases in patients. NSCLC has two sub-types including lung adenocarcinoma (LUAD) and lung squamous cancer (LUSC). Prognosis remains low and the 5-year survival rate is less than 25% in the USA. There have been many recent studies which reflect different factors that influence and impact the survival rate of lung cancer. Further research is required to understand the relationships between these factors and ultimately, devise treatments and therapies to improve the prognosis and survival rate of lung cancer patients.
Studies have shown KRAS mutation is the second most common mutation that occurs in NSCLC which involves KRAS mutant cancer cells suppressing the anti-tumor T cell response and therefore, avoid being attacked by the immune system allowing them to facilitate the progression of immune evasion. However, the molecular mechanism behind this activity remains relatively unknown and further studies are required to understand how KRAS mutations impact the survival rate and response to therapies in lung cancer patients. Other studies have demonstrated that the overactivation of epidermal growth factor receptor (EGFR) tyrosine kinases play a key role in the development of NSCLC. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) including gefitinib, afatinib, and osimertinib have been widely used in the treatment of NSCLC. Further studies have reflected the impact of smoking and how that can impact the treatment in EGFR-mutated NSCLC patients.
There are many factors that impact the overall survival of lung cancer patients. This Research Topic aims to generate a discussion of factors including specific molecular mechanisms, drug therapies and resistance as well as lifestyle and environmental factors that directly influence the overall survival rate of NSCLC patients. Topics of interest include:
-Impact of KRAS mutations in the progression of lung cancer
-Signalling pathways that may impact immunotherapy
-Influence of lifestyle and environmental factors on the survival of lung cancer
-EGFR inhibitors and how they impact survival for lung cancer patients
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Lung cancer is one of the most common malignancies in men and women and a cause for global mortality with approximately over 200,000 new cases diagnosed in 2020. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer responsible for over 80% of cases in patients. NSCLC has two sub-types including lung adenocarcinoma (LUAD) and lung squamous cancer (LUSC). Prognosis remains low and the 5-year survival rate is less than 25% in the USA. There have been many recent studies which reflect different factors that influence and impact the survival rate of lung cancer. Further research is required to understand the relationships between these factors and ultimately, devise treatments and therapies to improve the prognosis and survival rate of lung cancer patients.
Studies have shown KRAS mutation is the second most common mutation that occurs in NSCLC which involves KRAS mutant cancer cells suppressing the anti-tumor T cell response and therefore, avoid being attacked by the immune system allowing them to facilitate the progression of immune evasion. However, the molecular mechanism behind this activity remains relatively unknown and further studies are required to understand how KRAS mutations impact the survival rate and response to therapies in lung cancer patients. Other studies have demonstrated that the overactivation of epidermal growth factor receptor (EGFR) tyrosine kinases play a key role in the development of NSCLC. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) including gefitinib, afatinib, and osimertinib have been widely used in the treatment of NSCLC. Further studies have reflected the impact of smoking and how that can impact the treatment in EGFR-mutated NSCLC patients.
There are many factors that impact the overall survival of lung cancer patients. This Research Topic aims to generate a discussion of factors including specific molecular mechanisms, drug therapies and resistance as well as lifestyle and environmental factors that directly influence the overall survival rate of NSCLC patients. Topics of interest include:
-Impact of KRAS mutations in the progression of lung cancer
-Signalling pathways that may impact immunotherapy
-Influence of lifestyle and environmental factors on the survival of lung cancer
-EGFR inhibitors and how they impact survival for lung cancer patients
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
